253 related articles for article (PubMed ID: 26099344)
1. The immunomodulatory effects of intravenous immunoglobulin therapy in Kawasaki disease.
Burns JC; Franco A
Expert Rev Clin Immunol; 2015; 11(7):819-25. PubMed ID: 26099344
[TBL] [Abstract][Full Text] [Related]
2. Fine specificities of natural regulatory T cells after IVIG therapy in patients with Kawasaki disease.
Burns JC; Touma R; Song Y; Padilla RL; Tremoulet AH; Sidney J; Sette A; Franco A
Autoimmunity; 2015 May; 48(3):181-8. PubMed ID: 25822882
[TBL] [Abstract][Full Text] [Related]
3. Intravenous immunoglobulin induces IgG internalization by tolerogenic myeloid dendritic cells that secrete IL-10 and expand Fc-specific regulatory T cells.
Hsieh LE; Song J; Tremoulet AH; Burns JC; Franco A
Clin Exp Immunol; 2022 Jun; 208(3):361-371. PubMed ID: 35536993
[TBL] [Abstract][Full Text] [Related]
4. Intravenous immunoglobulin does not increase FcgammaRIIB expression on monocytes/macrophages during acute Kawasaki disease.
Ichiyama T; Ueno Y; Hasegawa M; Ishikawa Y; Matsubara T; Furukawa S
Rheumatology (Oxford); 2005 Mar; 44(3):314-7. PubMed ID: 15572393
[TBL] [Abstract][Full Text] [Related]
5. Th17- and Treg-related cytokine and mRNA expression are associated with acute and resolving Kawasaki disease.
Guo MM; Tseng WN; Ko CH; Pan HM; Hsieh KS; Kuo HC
Allergy; 2015 Mar; 70(3):310-8. PubMed ID: 25585854
[TBL] [Abstract][Full Text] [Related]
6. Immune-monitoring in Kawasaki disease patients treated with infliximab and intravenous immunoglobulin.
Burns JC; Song Y; Bujold M; Shimizu C; Kanegaye JT; Tremoulet AH; Franco A
Clin Exp Immunol; 2013 Dec; 174(3):337-44. PubMed ID: 23901839
[TBL] [Abstract][Full Text] [Related]
7. [Immunoglobulin therapy].
Ogata S; Ishii M
Nihon Rinsho; 2014 Sep; 72(9):1617-22. PubMed ID: 25518412
[TBL] [Abstract][Full Text] [Related]
8. [Immunoregulatory mechanisms of action of intravenous gammaglobulin in Kawasaki syndrome].
Marcinkiewicz J; Szymanowska Z; Mazurek A
Przegl Lek; 1998; 55(11):611-3. PubMed ID: 10216377
[TBL] [Abstract][Full Text] [Related]
9. Intravenous Immunoglobulin Therapy Restores the Quantity and Phenotype of Circulating Dendritic Cells and CD4
Wang N; Chen Z; Zhang F; Zhang Q; Sun L; Lv H; Wang B; Shen J; Zhou X; Chen F; Zhang B; Meng L; Zhou H; Bai Z; Huang J
Front Immunol; 2022; 13():802690. PubMed ID: 35222381
[TBL] [Abstract][Full Text] [Related]
10. Specificity of regulatory T cells that modulate vascular inflammation.
Franco A; Touma R; Song Y; Shimizu C; Tremoulet AH; Kanegaye JT; Burns JC
Autoimmunity; 2014 Mar; 47(2):95-104. PubMed ID: 24490882
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of action of intravenous immunoglobulin in the treatment of immune thrombocytopenia.
Crow AR; Song S; Siragam V; Lazarus AH
Pediatr Blood Cancer; 2006 Oct; 47(5 Suppl):710-3. PubMed ID: 16933274
[TBL] [Abstract][Full Text] [Related]
12. High Dose Intravenous IgG Therapy Modulates Multiple NK Cell and T Cell Functions in Patients With Immune Dysregulation.
McAlpine SM; Roberts SE; Heath JJ; Käsermann F; Issekutz AC; Issekutz TB; Derfalvi B
Front Immunol; 2021; 12():660506. PubMed ID: 34093549
[TBL] [Abstract][Full Text] [Related]
13. [Anti TNF-α (infliximab) treatment for intravenous immunoglobulin (IVIG) resistance patients with acute Kawasaki disease the effects of anticytokine therapy].
Saji T; Takatsuki S; Kobayashi T
Nihon Rinsho; 2014 Sep; 72(9):1641-9. PubMed ID: 25518416
[TBL] [Abstract][Full Text] [Related]
14. [Cytokines in Kawasaki disease].
Abe J
Nihon Rinsho; 2014 Sep; 72(9):1548-53. PubMed ID: 25518401
[TBL] [Abstract][Full Text] [Related]
15. Intravenous immunoglobulin therapy in vasculitis: speculation or evidence?
Aries PM; Hellmich B; Gross WL
Clin Rev Allergy Immunol; 2005 Dec; 29(3):237-45. PubMed ID: 16391399
[TBL] [Abstract][Full Text] [Related]
16. Kawasaki disease: a comprehensive review of treatment options.
Patel RM; Shulman ST
J Clin Pharm Ther; 2015 Dec; 40(6):620-5. PubMed ID: 26547265
[TBL] [Abstract][Full Text] [Related]
17. Possible mechanisms for intravenous immunoglobulin-associated hemolysis: clues obtained from review of clinical case reports.
Padmore R
Transfusion; 2015 Jul; 55 Suppl 2():S59-64. PubMed ID: 26174898
[TBL] [Abstract][Full Text] [Related]
18. Inflammatory cytokines as predictors of resistance to intravenous immunoglobulin therapy in Kawasaki disease patients.
Sato S; Kawashima H; Kashiwagi Y; Hoshika A
Int J Rheum Dis; 2013 Apr; 16(2):168-72. PubMed ID: 23773640
[TBL] [Abstract][Full Text] [Related]
19. Management of acute and refractory Kawasaki disease.
Tacke CE; Burgner D; Kuipers IM; Kuijpers TW
Expert Rev Anti Infect Ther; 2012 Oct; 10(10):1203-15. PubMed ID: 23199405
[TBL] [Abstract][Full Text] [Related]
20. Transcriptional regulation by infliximab therapy in Kawasaki disease patients with immunoglobulin resistance.
Ogihara Y; Ogata S; Nomoto K; Ebato T; Sato K; Kokubo K; Kobayashi H; Ishii M
Pediatr Res; 2014 Sep; 76(3):287-93. PubMed ID: 24964229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
